Permeation of Boswellia extract in the Caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1B3 and MRP2

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 2-3, 2009, Pages 275-284

  Krüger, Phillip ^a   Kanzer, Johanna ^b   Hummel, Jessica ^b   Fricker, Gert ^b   Schubert Zsilavecz, Manfred ^a,c   Abdel Tawab, Mona ^a  

^a ABDA Bundesvereinigung Deutscher Apothekerverbande   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Absorption; Boswellic acids; Caco 2; MRP2; OATP1B3; P glycoprotein; Permeability

Indexed keywords

11 KETO BETA BOSWELLIC ACID; 3 ACETYL 11 KETO BETA BOSWELLIC ACID; BOSWELLIA SERRATA EXTRACT; BOSWELLIC ACID; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B3; ORPHAN DRUG; PROPRANOLOL; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; BRAIN EDEMA; BRAIN TUMOR; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL;

ANILINE COMPOUNDS; ANIMALS; BOSWELLIA; CACO-2 CELLS; CELL LINE; DOGS; ELECTRIC IMPEDANCE; FLUORESCEINS; FLUORESCENT DYES; HUMANS; INTESTINAL ABSORPTION; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEIN; PERMEABILITY; PLANT EXTRACTS; PROPIONATES; QUINOLINES; SOLUBILITY; SULFOBROMOPHTHALEIN; TIGHT JUNCTIONS; TRANSFECTION; TRITERPENES; VERAPAMIL; XANTHENES;

EID: 58149168822     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.10.005     Document Type: Article

References (30)

1. Abdel Tawab M., Kaunzinger A., Bahr U., Karas M., Wurglics M., and Schubert-Zsilavecz M. Development of a high-performance liquid chromatographic method for the determination of 11-keto-beta-boswellic acid in human plasma. J. Chromatogr. Biomed. Appl. 761 2 (2001) 221-227
2. Abe T., Unno M., Onogawa T., Tokui T., Kondo T.N., Nakagomi R., Adachi H., Fujiwara K., Okabe M., Suzuki T., Nunoki K., Kakyo M., Nishio T., Sugita J., Asano N., Tanemaoto M., Seki M., Date f., Ono K., Kondo Y., Shiiba K., Suzuki M., Ohtani H., Shimosegawa T., Iinuma K., Nagura H., Ito S., and Matsuno S. LST-2 a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120 7 (2001) 1689-1699
3. Artursson P. Epithelial transport of drugs in cell culture. I. A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79 (1990) 476-482
4. Baldes C., Koenig P., Neumann D., Lenhof H.-P., Kohlbacher O., and Lehr C.-M. Development of a fluorescence-based assay for screening of modulators of human organic anion transporter 1 B3 (OATP1B3). Eur. J. Pharm. Biopharm. 62 (2005) 39-43
5. Buechele B., and Simmet T. Analysis of 12 different pentacyclic triterpenic acids from frankincense in human plasma by high-performance liquid chromatography and photodiode array detection. J. Chromatogr. B 795 2 (2003) 355-362
6. El-Sheikh A.A.K., van den Heuvel J.J.M.W., Koenderink J.B., and Russel F.G.M. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther. 320 (2007) 229-235
7. Förster F., Volz A., and Fricker G. Compound profiling for ABCC2 (MRP2) using fluorescent microplate assay system. Eur. J. Pharm. Biopharm. 69 1 (2008) 396-403
8. Francis M., Cristea M., and Winnik F. Polymeric micelles for oral drug delivery: why and how. Pure Appl. Chem. 76 7-8 (2004) 1321-1335
9. Gerhardt H., Seifert F., Buvari P., Vogelsang H., and Repges R.Z. Therapy of active Crohn disease with Boswellia serrata extract H 15. Gastroenterology 39 1 (2001) 11-17
10. Gupta I., Gupta V., Parihar A., Gupta S., Luedtke R., Safayhi H., and Ammon H.P.T. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur. J. Med. Res. 3 11 (1998) 511-514
11. Gupta I., Parihar A., Malhotra P., Singh G.B., Luedtke R., Safayhi H., and Ammon H.P.T. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur. J. Med. Res. 2 1 (1997) 37-43
12. Hirohashi T., Suzuki H., Chu X.-Y., Tamai I., Tsuji A., and Sugiyama Y. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). J. Pharmacol. Exp. Ther. 292 1 (1999) 265-292
13. Jani P., Halbert G.W., Langridge J., and Florence A.T. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 42 12 (1990) 821-826
14. Kimmatkar N., Thawani V., Hingorani L., and Khinyani R. Effect and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee-a randomized double blind placebo controlled trial. Phytomedicine 10 (2003) 3-7
15. Krüger P., Daneshfar R., Eckert G.P., Klein J., Volmer D., Bahr U., Müller W.E., Karas M., Schubert-Zsilavecz M., and Abdel-Tawab M. Metabolism of boswellic acids in vitro and in vivo. Drug Metab. Dispos. 36 6 (2008) 1135-1142
16. Kullak-Ublick G.A., Ismair M.G., Stieger V., Landmann L., Huber R., Pizzagalli F., Fattinger K., Meier P.J., and Hagenbuch B. Oganic-anion transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120 (2001) 525-533
17. Liversidge G.C., and Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125 (1995) 91-97
18. Meunier V., Bourrie M., Berger Y., and Fabre G. The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol. Toxicol. 11 (1995) 187-194
19. Neuhoff S., Ungell A.-L., Zamora I., and Artursson P. PH-dependent passive and active transport of acidic drugs across caco-2 cell monolayers. Eur. J. Pharm. Sci. 25 (2005) 220-221
20. Poeckel D., and Werz O. Boswellic acids: biological actions and molecular targets. Curr. Med. Chem. 13 28 (2006) 3359-3369
21. Potthast H., Dressmann J.B., Junginger H.E., Midha K.K., Oeser H., Shah V.P., Vogelpoel H., and Barends D.M. Biowaiver monograph for immediate release solid oral dosage forms. J. Pharm. Sci. 94 10 (2005) 2121-2131
22. Reising K., Meins J., Bastian B., Eckert G., Mueller W.E., Schubert-Zsilavecz M., and Abdel Tawab M. Determination of boswellic acids in brain and plasma by high-performance liquid chromatography/tandem mass spectrometry. Anal. Chem. 77 20 (2005) 6640-6645
23. Safayhi H., Mack T., Sabieraj J., Anazodo M., Subramanian L.R., and Ammon H.P.T. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J. Pharmacol. Exp. Ther. 261 3 (1992) 1143-1146
24. Sander O., Herborn G., and Rau R. Is H15 (resin extract of Boswellia serrata, "incense") a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study. Z. Rheumatol. 57 1 (1998) 11-16
25. Sharma S., Thawani V., Hingorani L., Shrivastava M., Bhate V.R., and Khiyani R. Pharmacokinetic study of 11-keto beta-boswellic acid. Phytomedicine 11 2-3 (2004) 1255-1260
26. Sterk V., Büchele B., and Simmet T. Effect of food intake on the bioavaliability of boswellic acids from a herbal preparation in healthy volunteers. Planta Med. 70 12 (2004) 1155-1160
27. Weber C.C., Reising K., Mueller W.E., Schubert-Zsilavecz M., and Abdel Tawab M. Modulation of Pgp function by boswellic acids. Planta Med. 72 6 (2006) 507-513
28. Winking M., Sarikaya S., Rahmanian A., Jodicke A., and Boker D.K. Boswellic acids inhibit glioma growth: a new treatment option?. J. Neurooncol. 46 2 (2000) 97-103
29. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm. Res. 14 6 (1997) 763-766
30. Zelcer N., Huisman M.T., Reid G., Wielinga P., Breedveld P., Kuil A., Knipscheer P., Schellens J.H., Schinkel A.H., and Borst P. Evidence for two interacting ligand binding sites in human multidrug resistance protein MRP2 (ATP binding cassette C2). J. Biol. Chem. 278 (2003) 23538-23544